GlassScriptPhysician profile
Noor Yono
NPI 1679896526
$61,793.82
in general payments reported to CMS, 2019-2025
70 companies · $1,695 in 2025
The $1,695 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $9,418 · 2021: $20K · 2022: $11K · 2023: $6,833 · 2024: $2,234 · 2025: $1,695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,648 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,825 · Travel and Lodging: $114 · Consulting Fee: $100 · Education: $74.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,647.94 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,825.00 |
| Travel and Lodging | $113.97 |
| Consulting Fee | $100.00 |
| Education | $74.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17,677.86 | 2019-2025 | Ubrelvy, Qulipta, Botox |
| Allergan, INC. | $10,206.49 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $8,284.79 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $6,561.45 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $1,684.89 | 2022 | |
| Genzyme Corporation | $1,415.93 | 2019-2025 | |
| Biogen, INC. | $1,340.40 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Novartis Pharmaceuticals Corporation | $1,327.46 | 2019-2025 | |
| Ucb, INC. | $1,050.00 | 2019-2025 | Zilbrysq, Rystiggo, Nayzilam |
| Alexion Pharmaceuticals, INC. | $1,007.83 | 2019-2025 | Ultomiris, Soliris |
| Zyla Life Sciences, INC. | $756.22 | 2019-2020 | |
| Pfizer INC. | $739.76 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $705.12 | 2019-2025 | Nuplazid |
| Argenx US, INC. | $620.43 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Mdd US Operations, LLC | $544.78 | 2019-2024 | Apokyn, Apokyn |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $532.26 | 2019-2024 | Austedo Xr, Austedo |
| Kyowa Kirin, INC. | $438.04 | 2020-2024 | Nourianz |
| Eisai INC. | $425.32 | 2019-2025 | |
| Sk Life Science, INC. | $352.40 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $345.92 | 2019-2021 | |
| Csl Behring | $279.30 | 2019-2025 | Hizentra |
| Aquestive Therapeutics, INC. | $265.36 | 2019-2021 | |
| Genentech USA, INC. | $259.70 | 2019-2025 | Enspryng, Ocrevus, Ocrevus Zunovo |
| Neurelis, INC. | $253.56 | 2021-2025 | Valtoco |
| Emd Serono, INC. | $242.54 | 2019-2024 | Mavenclad |
| Jazz Pharmaceuticals INC. | $236.62 | 2019-2024 | |
| Lundbeck LLC | $222.40 | 2019-2024 | Rexulti, Vyepti |
| Lilly USA, LLC | $221.16 | 2019-2022 | |
| Bausch Health US, LLC | $218.31 | 2019-2020 | |
| Celgene Corporation | $217.41 | 2020-2025 | Zeposia |
| Tanabe Pharma America, INC. | $211.69 | 2019-2025 | Radicava |
| Janssen Pharmaceuticals, INC | $205.73 | 2020-2022 | |
| Medtronic, INC. | $190.00 | 2021-2023 | Indigo, Skeeter |
| Amgen INC. | $173.91 | 2019-2025 | Uplizna, Aimovig |
| Impel Pharmaceuticals INC. | $161.82 | 2022 | |
| Greenwich Biosciences, INC. | $155.26 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $153.48 | 2019-2023 | Ingrezza, Ongentys |
| Merz North America, INC. | $149.05 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $140.90 | 2020-2025 | Rytary, Ongentys 50mg Capsules 30, Crexont |
| Acorda Therapeutics, INC | $130.18 | 2019-2023 | Inbrija |
| Merz Pharmaceuticals, LLC | $122.51 | 2021-2025 | Inbrija, Xeomin |
| Livanova USA, INC. | $122.47 | 2019 | |
| Grifols USA, LLC | $119.52 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $114.49 | 2019-2023 | |
| Ge Healthcare | $111.89 | 2019-2024 | |
| Avanir Pharmaceuticals, INC. | $88.23 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $85.20 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.55 | 2021-2025 | Hyqvia |
| Janssen Biotech, INC. | $81.46 | 2025 | |
| Alfasigma USA, INC. | $63.74 | 2020-2022 | |
| Microtransponder, INC. | $61.28 | 2024-2025 | |
| Arbor Pharmaceuticals, INC. | $57.82 | 2019-2021 | |
| Tg Therapeutics, INC. | $51.12 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $50.23 | 2023 | Aptiom |
| Horizon Therapeutics Plc | $49.86 | 2022-2023 | Uplizna |
| Solta Medical, A Division of Bausch Health US, LLC | $47.89 | 2025 | |
| Octapharma USA, INC. | $38.70 | 2021-2022 | |
| Avion Pharmaceuticals | $37.94 | 2022-2023 | Dhivy |
| Assertio Therapeutics, INC. | $37.62 | 2020 | |
| Banner Life Sciences, LLC | $37.05 | 2022 | |
| Promius Pharma LLC | $36.33 | 2019 | |
| Otter Pharmaceuticals, LLC | $33.31 | 2025 | Sympazan |
| Aucta Pharmaceuticals, INC. | $31.05 | 2024-2025 | Motpoly Xr |
| Insightec,INC | $20.74 | 2023 | Exablate |
| Otsuka America Pharmaceutical, INC. | $20.70 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $20.05 | 2020 | |
| Vanda Pharmaceuticals INC. | $19.48 | 2025 | Ponvory |
| Idorsia Pharmaceuticals US INC | $16.96 | 2023 | Quviviq |
| Catalyst Pharmaceuticals, INC. | $15.42 | 2020 | |
| Almatica Pharma LLC | $13.48 | 2023 | Gralise |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noor Yono listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.